Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...

Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study ...

A pancreatic cancer drug is showing promising signs of a possible breakthrough after a clinical trial found it nearly doubled ...

Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival -- Company intends to include these data in a future New Drug Application submission to the ...

Daraxonrasib improved survival in metastatic pancreatic cancer in Phase III, signaling meaningful progress for therapies targeting RAS‑driven disease.

Revolution Medicines announces positive Phase 3 clinical trial results for its pancreatic cancer treatment.

Pancreatic adenocarcinoma is by far the most common subtype of pancreatic cancer, but there are many other subtypes. Your pancreas is an organ behind your stomach that helps with digestion and hormone ...

Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response Pancreatic ...

Zenocutuzumab is the first FDA-approved treatment for NRG1-positive NSCLC and pancreatic adenocarcinoma. The eNRGy study demonstrated a 33% overall response rate in NSCLC and 40% in pancreatic ...